Identifying Biomarkers in Alzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorChinese University of Hong Kong
About this trial
Alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. With the ageing population, AD is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. AD is the only cause of death among the top ten causes that has no prevention or cure . It is believed that novel treatment of AD needs to start early or even at the prodromal stage in order to be effective. Therefore, there is an urgent need to find accurate methods of early detection before patients with AD develop clinical dementia.
This study aims to identify biomarkers for AD in local Chinese population. this study hypothesizes blood-based proteomics, retinal imaging, ASL-MRP and tau PET can improve the accuracy and staging of AD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Chinese ethnicity
[For dementia group, clinical diagnosis of "probable Alzheimer's disease" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)
Disqualifiers
Clinical diagnosis of non-AD dementia
contraindication for MRI or PET
Trial population
AD subjects will be recruited from neurology cognitive disorder clinic of Prince of Wales Hospital. Age match normal control will be recruited from existing normal control studies.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
300 Participants
are grouped into 4 trial groupsGroup A: Normal cognition
Group B: Subjective Cognitive Disorder
Group C: Mild Cognitive Impairment
Group D: Dementia
Trial outcomes
Primary outcomes
1
The score change in Hong Kong List Learn Test (HKLLT)
The Hong Kong List Learn Test would be administered to assess the cognitive status for all group of study subjects
Time frame
Baseline, 1 year, 2 year, 3 year ,4 year ,5 year and 6 year visit after baseline visit2
The score change in Montreal Cognitive Assessment Hong Kong (HK-MoCA)
The Montreal Cognitive Assessment Hong Kong would be administered to assess the cognitive status for all group of study subjects
Time frame
Baseline, 1 year, 2 year, 3 year ,4 year ,5 year and 6 year visit after baseline visit3
The score change Clinical Dementia Rating (CDR)
The Clinical Dementia Rating would be administered to assess the cognitive status for all group of study subjects
Time frame
Baseline, 1 year, 2 year, 3 year ,4 year ,5 year and 6 year visit after baseline visit4
Amount of amyloid β with 11C-Pittsburgh compound B
Positron emission tomography imaging with 11C-Pittsburgh compound B would quantify the amount of amyloid β. Amyloid β is one of the biomarkers associate Alzheimer Disease
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov